
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis is a leading medical technology manufacturer and distributor focused on orthopedic and recovery science solutions that generate better patient outcomes. With strong performance in both the Prevention & Recovery and Reconstructive segments, the company is experiencing steady above-market growth, backed by its strong portfolio of new products. Despite the 2H26 guidance being 4Q loaded, the company remains on track to deliver on its revenue and earnings targets, driven by margin expansion, improving free cash flow, and a robust pipeline of innovative products. The company's current discount to its peer group is unwarranted, and we believe shares are trading at a bargain.
Bears say
Enovis is facing major challenges in terms of organic top-line growth and profitability, which may lead to further multiple contraction and limit share performance in the face of its relatively inexpensive valuation. This is due to declining organic growth, changes in sales force structure, and decreases in profitability. There are also risks of losing market share to competitors, manufacturing risks, slower (or faster) adoption of robotics in orthopedics, and limitations on margin expansion and salesforce disruptions.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares